Entolimod - Cleveland BioLabs

Drug Profile

Entolimod - Cleveland BioLabs

Alternative Names: CBLB 502

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cleveland BioLabs
  • Class Anti-ischaemics; Antidotes; Antineoplastics; Chemoprotectants; Peptides; Radioprotectives; Recombinant proteins
  • Mechanism of Action Apoptosis inhibitors; NF-kappa B modulators; Toll-like receptor 5 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • No development reported Acute radiation syndrome; Cancer; Radiation injuries; Reperfusion injury

Most Recent Events

  • 28 Aug 2018 No recent reports of development identified for phase-I development in Acute-radiation-syndrome in USA (IM, Injection)
  • 28 Aug 2018 No recent reports of development identified for phase-I development in Cancer(Inoperable/Unresectable, Late-stage disease) in Russia (IM, Injection)
  • 28 Aug 2018 No recent reports of development identified for phase-I development in Cancer(Inoperable/Unresectable, Late-stage disease) in USA (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top